Practical guidance for caregivers managing clinical trial logistics, advocacy, and self-care.
If you're a caregiver for someone with a rare disease, you're often the one doing the research, asking the questions, and managing the logistics. When a clinical trial enters the picture, your role becomes even more important. You may be the one who first identifies a relevant trial, coordinates with the research site, arranges travel, and monitors how your loved one responds to the treatment.
For pediatric trials and trials involving adults with cognitive impairment, caregivers are frequently the primary point of contact and legally authorized representative. Understanding what a trial involves helps you advocate effectively and make informed decisions together with the medical team.
Start by understanding the current treatment options for the specific condition. Disease-specific advocacy organizations are often the single best resource. Groups like NORD, the National Organization for Rare Disorders, maintain patient navigators who can help identify trials and connect families with research teams. Many advocacy foundations for specific diseases (Cystic Fibrosis Foundation, Sickle Cell Disease Association, Foundation Fighting Blindness, among many others) maintain their own trial databases and patient registries that feed directly into researcher recruitment pipelines.
ClinicalTrials.gov lists every registered trial in the United States and many international studies. Trial Friend simplifies this search for rare diseases specifically, showing which trials are actively recruiting and where sites are located. When you find a promising trial, your next step is contacting the research coordinator listed on the trial record. Don't wait for your doctor to do this. Coordinators expect calls from patients and families and can quickly tell you whether the trial might be a fit.
Keep a running list of trials you've contacted, including the coordinator's name, eligibility criteria, and timeline. Trials open and close enrollment unpredictably, so having several options tracked simultaneously gives you the best chance of finding a match.
Clinical trials for rare diseases often require traveling to specialized centers. Before enrolling, get a clear picture of the visit schedule: how many visits are required, how long each takes, and whether any can be done remotely or at a local lab. Some trials now offer decentralized elements like home nursing visits, telemedicine check-ins, and direct-to-patient drug delivery.
Ask the research coordinator about travel assistance. Many trial sponsors reimburse travel, lodging, and meal costs. NORD's patient travel assistance program, the HealthWell Foundation, and disease-specific foundations may also provide financial support. Some organizations like the National Patient Travel Center coordinate free or reduced-cost air travel for patients needing to reach distant trial sites.
Document everything. Keep copies of all informed consent forms, test results, medication logs, and communication with the research team. If your loved one experiences side effects or changes in condition, note the date, time, and details. This documentation is valuable both for the trial team and for your own medical records.
For caregivers of children with rare diseases, clinical trial participation involves additional regulatory and emotional layers. The FDA requires that children old enough to understand provide formal assent (the child's affirmative agreement to participate), typically starting around age 7, in addition to parental permission. Assent forms are written in age-appropriate language, and the research team should walk through the trial directly with your child as well as with you.
School disruption is a real consideration. Trial visits at distant academic centers can mean missed school days and the need for a 504 plan or IEP accommodation for chronic medical absences. Several states have explicit statutes protecting students with chronic illness from truancy proceedings, but the protection often has to be invoked by name. Our detailed walkthrough of 504 plans, IEPs, and rare-disease school accommodations covers what gets approved, the paperwork sequence that wins, and the parent mistakes that cost families months. Sibling care during multi-day visits often becomes a logistics puzzle worth planning out before the first visit, not in the moment.
Pediatric trials sometimes have parent-child interaction protocols built in, where the research team will ask both you and your child the same question to compare answers. This is a quality-control measure, not a test of your parenting. Be honest about the differences between what your child reports and what you observe, since the research team needs both perspectives to interpret the data correctly.
For patients who cannot make their own treatment decisions because of cognitive impairment, the trial team requires a Legally Authorized Representative (LAR), typically a healthcare power of attorney holder, a court-appointed guardian, or in some cases an immediate family member acting under state surrogate consent laws. The IRB will review the LAR documentation as part of the consent process, and you may be asked to provide proof of authority in writing.
If you're acting as LAR, your obligation is to make the decision the patient would have made for themselves if they could speak, not the decision you would make in their place. This is sometimes called substituted judgment. For many rare diseases (advanced Huntington disease, severe intellectual disability syndromes, late-stage neurodegenerative conditions), this distinction matters because the patient may have expressed views about clinical trial participation when they could communicate, and those views still bind the LAR's choice.
The Office for Human Research Protections (OHRP), the federal office that oversees research ethics, has detailed guidance on LAR rules that varies by state. Your trial coordinator and the IRB office can clarify what's specifically required in your jurisdiction. Some states require court-appointed guardianship for research consent even when a healthcare power of attorney is sufficient for medical treatment decisions.
You're often the most consistent observer of how your loved one is doing day to day, and the research team relies on that observation. The tools that work in practice are simple but need to be used consistently.
Keep a symptom diary with dates, times, and severity scores for the symptoms the trial is targeting and for any new symptoms that appear. Apps like CareZone, Symple, or even a shared Google Sheet work fine. Bring it to every visit. Keep a medication log including the trial drug, all current medications, and supplements with timing, since drug interactions are a common reason for protocol amendments. Maintain a side effect log distinguishing "definitely from the trial drug" from "might be unrelated"; the research coordinator decides what gets reported as a formal adverse event, but your detailed observations help that decision. Photographs documenting visible symptoms (rashes, swelling, mobility changes) over time, dated, are evidence the research team can use directly.
When something feels wrong, contact the research coordinator within 24 hours, not at the next scheduled visit. Most trials have 24/7 contact lines for adverse events. Using them is exactly what they're for, and reporting early matters more than reporting completely.
Clinical trials sometimes don't produce the result you hoped for. The treatment may have no effect on your loved one, your loved one may not tolerate it, or the data may show the drug isn't beneficial in the broader population and the trial is stopped. None of these outcomes is a failure of your advocacy.
The transition out of a trial includes several next steps that the research team can help with. If the drug was approved for a different condition, off-label use may be available through a clinician willing to prescribe. If the drug remained experimental, expanded access programs, compassionate use applications, or named patient programs may continue access for some patients. The research coordinator should help facilitate this even after the formal trial ends. Other trials in the same disease space may be enrolling, and the coordinator often knows about them.
Emotionally, the bridge between "trying a trial" and "returning to standard care" is often harder than expected. Many advocacy organizations run support groups specifically for families whose trial experience didn't produce the hoped-for result. Asking the research social worker for these connections is worth doing before you leave the trial, not weeks later when you're trying to find them on your own.
Caregiver burnout is real and common, especially in the rare disease community where the emotional and logistical demands are relentless. A clinical trial adds appointments, travel, uncertainty about whether the treatment is working, and the emotional weight of hoping for a breakthrough. You cannot advocate effectively for your loved one while running on empty. Caregiver mental health is medical care, not optional.
The Caregiver Action Network and NORD's caregiver resources offer phone-based support designed for rare disease caregivers, and many disease-specific organizations run caregiver support groups (in-person and virtual). For active anxiety, depression, or sustained distress, individual therapy is often more effective than peer support alone. Telehealth therapy expanded significantly during 2020 to 2024, and most states now have therapists who specialize in chronic illness and caregiver burden. The American Psychological Association's locator service filters for chronic illness specialty.
Respite care services give you time off from caregiving without disrupting your loved one's care. The ARCH National Respite Network maintains a state-by-state directory of respite providers, including some specifically for rare disease families. Some Medicaid programs cover respite care, while commercial insurance varies. Some clinical trial sites have social workers on staff who can connect you with local respite and counseling resources. Use them.
A caregiver during a clinical trial typically manages logistics (scheduling, travel, lodging), tracks medication adherence and symptom changes, attends study visits to take notes and ask follow-up questions, communicates with the research coordinator between visits, advocates for the participant if questions arise, and provides emotional support throughout the trial. Many sponsors now formally recognize caregivers in their consent and patient experience documentation, and trial sites often have a dedicated caregiver liaison.
Yes. Parents and legal guardians attend clinical trial visits for their children. Many pediatric trial sites also accommodate siblings and have child-life specialists to help children cope with procedures. The informed consent and assent process must include both parental permission and (for children old enough to understand) the child's formal assent. Most pediatric trials reimburse family travel and provide on-site or nearby family lodging.
Many clinical trials cover caregiver travel and lodging, especially for rare disease trials at distant academic centers. Coverage typically includes airfare or mileage, hotel for multi-night visits, meals during travel, and sometimes a per-visit caregiver stipend. The exact reimbursement schedule must be disclosed in the informed consent form. The National Patient Travel Center, Mercy Medical Angels, and similar nonprofits provide additional travel assistance for caregivers when sponsor coverage is limited.
A Legally Authorized Representative (LAR) is a person legally authorized under applicable state law to provide informed consent on behalf of a prospective participant who lacks the capacity to consent (such as an adult with severe cognitive impairment or active psychosis). State laws govern who qualifies as an LAR. The participant must still be given the opportunity to assent or dissent in a manner consistent with their abilities. LAR provisions are detailed in 45 CFR 46 and FDA Good Clinical Practice guidance.
To track a loved one's response to a clinical trial drug, keep a daily log of symptoms, medication times, side effects, mood, sleep, and any changes in baseline function. Many trials provide structured patient diaries (paper or app-based) for protocol-specific outcomes. Photographs and short videos can document visible symptoms, gait, or skin changes that are hard to describe in words. Bring this data to every visit and share it with the research team, since it is sometimes the only longitudinal record of between-visit changes.
Support for caregiver burnout in clinical trials includes phone-based and online support through the Caregiver Action Network and NORD's caregiver resources, individual therapy (with chronic illness specialty therapists locatable through the American Psychological Association directory), peer support groups run by disease-specific foundations, respite care through the ARCH National Respite Network, and on-site social work support at most trial sites. Caregiver mental health is medical care, not optional, and effective trial advocacy depends on caregiver well-being.
If a clinical trial drug does not work for your loved one, the trial team helps transition back to standard care, often including a structured taper schedule, follow-up safety visits to monitor for delayed adverse events, and a discussion of other trial options or off-label medications. Patient organizations frequently run support groups specifically for participants who did not respond. The relationship with the specialist trial team often persists after the trial ends and can guide future treatment decisions.
Yes. Under the federal Family and Medical Leave Act (FMLA), eligible employees can take up to 12 weeks of unpaid, job-protected leave per year to care for a spouse, child, or parent with a serious health condition (which includes most rare diseases and most clinical trial participation). Some states (California, New Jersey, New York, and others) have additional paid family leave programs. The Department of Labor FMLA Fact Sheet 28 details eligibility and process.